Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516017 | 0.78 | NR3C1 (0.61) | NR3C1PGRNR3C2ALDH1A1 | |
| SCHEMBL4526068 | 0.77 | NR3C1 (0.70) | NR3C1KMT2APGRNR3C2ALDH1A1 | |
| SCHEMBL4529437 | 0.76 | NR3C1 (0.64) | NR3C1KMT2APGRNR3C2ALDH1A1 | |
| SCHEMBL4504090 | 0.75 | NR3C1 (0.60) | NR3C1PGRNR3C2 | |
| SCHEMBL4510346 | 0.75 | NR3C1 (0.60) | NR3C1RAB9APGRNR3C2MAPT | |
| SCHEMBL4528546 | 0.73 | NR3C1 (1.00) | NR3C1PGRNR3C2 | |
| SCHEMBL25859288 | 0.73 | KMT2A (0.49) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL4512209 | 0.73 | NR3C1 (0.64) | NR3C1PGRNR3C2 | |
| SCHEMBL8858361 | 0.73 | MAPT (0.54) | KMT2ANPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL13533379 | 0.72 | MAPT (0.58) | KMT2ANPC1RAB9AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885L3MBTL1 4844/4885KMT2A 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.